Set up on an industrial estate in Telford, the centre has carried out almost 300,000 tests in just over two years.

The company behind the test said there were positive signs that some of the most aggressive cancers could be prevented.

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) trial of its Galleri test missed its primary endpoint.  | Grail’s shares ...

The screening—known as a liquid biopsy—is being rolled out to around 15,000 patients with suspected lung cancer, NHS England has announced. There are also plans to expand it to advanced breast cancer ...

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

Midwife Sarah Joy Owen explains how the day 5 heel prick works, what conditions it screens for and what happens if further ...

A controversial blood test that promises to detect multiple cancers in their early stages failed to meet a key trial endpoint of a significant reduction in stage III-IV cases. Investors in the US ...

The alert comes as research shows around one in two UK adults are affected by the health condition ...

A flurry of such tests that look for multiple cancers with a prick are in various stages of development. The one that is ...

Another challenge facing test designers is that early detection may not necessarily save lives. A crucial factor, and something that is still unknown about the new multi-cancer tests, is whether they ...